Matthew Frank, MD, PhD
Articles
Dr Frank on the Background of Investigating CAR22 Therapy in Relapsed/Refractory LBCL
August 31st 2023Matthew Frank, MD, PhD, discusses findings from prior research investigating a CD22-directed CAR T-cell therapy that informed the rationale for launching a phase 1 trial with this agent in patients with relapsed/refractory large B-cell lymphoma.
Read More
Dr Frank on Sequencing Questions With CAR22 in Relapsed/Refractory LBCL
August 4th 2023Matthew J. Frank, MD, PhD, discusses remaining questions regarding treatment sequencing following preliminary results from a phase 1 trial of a CD22-directed CAR-T therapy in relapsed/refractory large B-cell lymphoma.
Read More
Dr. Frank on the Rationale for CD22-Targeted CAR T-cell Therapy After CD19 Relapse in LBCL
February 23rd 2023Matthew Frank, MD, PhD, discusses the rationale for investigating CD22-directed CAR-T cell therapy in adult patients with large B-cell lymphoma who relapsed after or were refractory to CD19-directed CAR T-cell therapy.
Read More
Dr. Frank on CD22 CAR T-cell Therapy in Relapsed LBCL
February 17th 2023Matthew Frank, MD, PhD, discusses findings from a single-institution phase 1 trial investigating autologous CAR T cells targeting CD22 in adults with large B-cell lymphoma, including those who relapse after or are refractory to CD19-directed CAR T-cell therapy.
Read More
